BE-ABP

BE-ABP
Name	BE-ABP

BE-ABP.

Introduction

BE-ABP is a synthetic arylalkyl benzoyl derivative investigated in medicinal chemistry and toxicology contexts. It has been discussed in studies alongside compounds evaluated at institutions such as National Institutes of Health, Harvard University, University of Cambridge, Massachusetts Institute of Technology, and Stanford University. Interest in BE-ABP has arisen in literature intersecting research programs at World Health Organization, European Medicines Agency, and industrial laboratories including Roche, Pfizer, GlaxoSmithKline, and Novartis. Reviews and conference reports from venues such as American Chemical Society, Gordon Research Conference, International Union of Pure and Applied Chemistry, and Royal Society of Chemistry have summarized related series of arylbenzoyl compounds.

Chemical Structure and Properties

The core scaffold of BE-ABP comprises an arylbenzoyl motif fused to an alkylated pyridine-like or phenyl ring, exhibiting conjugated pi-systems similar to structures reported by groups at California Institute of Technology and ETH Zurich. Its calculated formula and molecular weight place it alongside small-molecule pharmacophores studied at Broad Institute and Scripps Research Institute. Spectroscopic fingerprints draw comparisons with spectra catalogued in databases maintained by National Center for Biotechnology Information, Chemical Abstracts Service, and Protein Data Bank depositors. Physicochemical parameters such as logP, pKa, and solubility have been characterized using instrumental platforms from Agilent Technologies and Bruker and compared with standards used at European Organization for Nuclear Research for analytical method development.

Synthesis and Production

Syntheses of BE-ABP variants follow convergent routes reported in synthetic methodology literature from groups at California Institute of Technology, University of Oxford, and Columbia University. Typical sequences involve Friedel–Crafts-type acylations, palladium-catalyzed cross-couplings exemplified by protocols from F. A. Miró, and late-stage functionalization techniques popularized by researchers at ETH Zurich and University of California, Berkeley. Reagents and catalysts cited in methods include palladium complexes procured from vendors associated with Sigma-Aldrich and ligand systems described in patents assigned to Bristol-Myers Squibb and Johnson & Johnson. Scale-up studies reference facilities at National Institute for Pharmaceutical Technology and Education and pilot plants affiliated with Merck & Co..

Mechanism of Action

Proposed mechanisms for BE-ABP activity draw on paradigms developed in signalling and enzymology research at Massachusetts General Hospital, Johns Hopkins University, and Monash University. Binding models utilize structural templates from crystallography efforts archived by Protein Data Bank contributors and docking workflows popularized by groups at University of Toronto and University of California, San Diego. Hypotheses include reversible occupancy of hydrophobic pockets analogous to sites studied in enzymes like cytochrome families characterized at Max Planck Institute for Biochemistry and receptor classes investigated at The Scripps Research Institute. Mechanistic investigations often cite comparative compounds from literature associated with University of Pennsylvania, Yale University, and Imperial College London.

Biological Effects and Toxicity

In vitro and in vivo studies performed in laboratories affiliated with National Institutes of Health, University of Cambridge, Karolinska Institutet, and University of Tokyo report dose-dependent effects on cell viability, mitochondrial function, and signal transduction pathways. Toxicological profiles reference assays and guidelines from Organisation for Economic Co-operation and Development, Food and Drug Administration, and European Medicines Agency. Comparative toxicology invokes benchmark compounds evaluated by Centers for Disease Control and Prevention and toxicogenomics datasets from National Toxicology Program. Case reports and preclinical safety summaries parallel assessments published by researchers at Vanderbilt University, Duke University, and McGill University.

Applications and Uses

BE-ABP and analogues have been explored as lead series in drug discovery campaigns at Novartis, Pfizer, GlaxoSmithKline, and academic screening centers such as Broad Institute and Wellcome Sanger Institute. Potential applications cited include modulation of enzyme families and receptor subtypes targeted in translational programs at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Center. Chemical biology studies at Cold Spring Harbor Laboratory and Los Alamos National Laboratory have used BE-ABP-like probes to interrogate pathways studied in oncology, infectious disease, and neuroscience contexts exemplified by work at Salk Institute for Biological Studies and Howard Hughes Medical Institute investigators.

Regulation and Safety Considerations

Regulatory status and safety controls for BE-ABP analogues are informed by frameworks from Food and Drug Administration, European Medicines Agency, Health Canada, and Medicines and Healthcare products Regulatory Agency. Laboratory handling follows standards articulated by Occupational Safety and Health Administration, National Institute for Occupational Safety and Health, and institutional biosafety committees at universities such as University of California, San Francisco and University of Michigan. Disposal and environmental impact assessments reference methodologies from Environmental Protection Agency and compliance guidance published by United Nations Environment Programme and International Labour Organization.

Category:Chemical compounds